FindTrial
Sign In

To see if patient clinical fitness or melphalan pharmacology affects the outcomes autologous hematopoietic cell transplantation for plasma cell myeloma

Association of clinical frailty, melphalan pharmacokinetics and pharmacogenomics with outcomes post high dose therapy and autologous hematopoietic cell transplantation for plasma cell myeloma.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/08/015354
Enrollment
50
Registered
2018-08-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with Multiple Myeloma undergoing Autologous stem cell transplantation.

Interventions

None listed

Sponsors

Department of Science and Technology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All adult patients ( >18 years of age) of multiple myeloma undergoing autologous HCT with melphalan conditioning will be included in the study.

Exclusion criteria

Exclusion criteria: Any patient not giving consent for the study.

Design outcomes

Primary

MeasureTime frame
Progression free survivalTimepoint: 30 days post transplant 100 days post transplant Time to progression Time to death—

Secondary

MeasureTime frame
Overall survivalTimepoint: 1 year—

Countries

India

Contacts

Public ContactRam V Nampoothiri

Dept of Internal Medicine, PGIMER, Chandigarh, India

deepesh.kem@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026